Product
Low dose A/H2N3c + standard dose MF59
1 clinical trial
6 indications
Indication
InfluenzaIndication
HumanIndication
InfectionsIndication
Respiratory Tract InfectionsIndication
Virus DiseasesIndication
Viral InfectionClinical trial
A Phase 1, Randomized, Observer-Blind, Multi-Center, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Subunit Influenza Virus Vaccine in Healthy Subjects 18 Years and AboveStatus: Recruiting, Estimated PCD: 2024-11-01